News
-
-
-
COMMUNIQUÉ DE PRESSE
Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG
BRAIN Biotech AG announces successful outcomes at the Annual General Meeting 2024, including approval of silent partnership with Hessen. CEO and Chairman express optimism for future growth and targets -
-
-
COMMUNIQUÉ DE PRESSE
Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials
BRAIN Biotech AG and AMSilk collaborate on protein engineering for performance materials, registering their first patent application. The strategic partnership aims for sustainable bio-based solutions in the textile industry -
-
-
COMMUNIQUÉ DE PRESSE
BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for the financing of further growth initiatives
BRAIN Biotech AG successfully placed EUR 5.0 million convertible bond for financing of growth initiatives. The bonds have an interest rate of 6.52% p.a. and a maturity date of 5 September 2026 -
